Yael Hayon - Sep 7, 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
VP, Research & Development
Signature
/s/ Eyal Rubin, POA
Stock symbol
PLX
Transactions as of
Sep 7, 2022
Transactions value $
$0
Form type
4
Date filed
9/9/2022, 05:03 PM
Next filing
Aug 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Options (Right to Buy) Award $0 +250K $0.00 250K Sep 7, 2022 Common Stock 250K $1.03 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
F2 Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030.